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ScienceDirectMetal ions are known to act as catalytic centres in metallo-
enzymes. On the other hand, low-molecular-weight metal
complexes are widely used as catalysts in chemical systems.
However, small catalysts do not have a large protein ligand to
provide substrate selectivity and minimize catalyst poisoning.
Despite the challenges that the lack of a protein ligand might
pose, some success in the use of metal catalysts for
biochemical transformations has been reported. Here, we
present a brief overview of such reports, especially involving
catalytic reactions in cells. Examples include C–C bond
formation, deprotection and functional group modification,
degradation of biomolecules, and redox modulation. We
discuss four classes of catalytic redox modulators:
photosensitizers, superoxide dismutase mimics, thiol oxidants,
and transfer hydrogenation catalysts. Catalytic metallodrugs
offer the prospect of low-dose therapy and a challenging new
design strategy for future exploration.
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Introduction
Metal-based catalysts, metallo-enzymes, are well known
in natural biological systems. These are often based on
transition metal ions surrounded by proteins, with sites
carefully designed to allow the selective recognition of
substrates, protecting somewhat the metal ion from poi-
soning. Examples include manganese, iron, copper, zinc
and molybdenum in all major classes of enzymes: oxidor-
eductases, transferases, hydrolases, lyases, isomerases and
ligases.
The potential value of using natural metallo-enzymes or
synthetic metal catalysts as drugs has already been
recognized. The enzyme SOD for example has been in
clinical trials as an oral agent for the treatment of
age-related macular degeneration (NCT00800995) [1].Current Opinion in Chemical Biology 2015, 25:172–183 Interestingly the MnII MRI contrast agent Mangafodipir
(MnDPDP) also possesses SOD activity, and Calmanga-
fodipir (Ca4Mn(DPDP)5) is in Phase II clinical trials
(NCT01619423) for treatment of metastatic colorectal
cancer [1].
Metallo-drugs with catalytic properties can potentially be
administered in smaller doses and with lower toxicity.
Furthermore, catalytic drugs are likely to have novel
mechanisms of action which might circumvent the de-
velopment of drug resistance. However, low-molecular-
weight catalysts are known to be easily poisoned in the
presence of nucleophiles [2]. Retaining the activity of
metal-based catalysts in biological media is, therefore,
challenging on account of the presence of many biomo-
lecules. Despite the difficulties, four major groups of
‘catalytic metallodrugs’ have been explored recently with
some remarkable successes, those relating to C–C bond
formation, deprotection and functional group modifica-
tion, degradation of biomolecules, and redox modulation.
We discuss four classes of catalytic redox modulators:
photosensitizers, superoxide dismutase mimics, thiol oxi-
dants and transfer hydrogenation catalysts. The potential
of these catalytic systems to progress from model reac-
tions, to cellular and eventually in vivo activity and to
become approved drugs, is of particular interest (Table 1).
Formation of C–C bonds
Reactions such as azide–alkynyl cycloadditions [3],
Suzuki–Miyaura [4–7] or Sonogashira [8] cross-couplings
have been explored as synthetic tools for C–C bond
formation in vitro and in vivo. For example, Pd0 nano-
particles can carry out Suzuki–Miyaura cross-coupling
reactions inside living cells. The nanoparticles can be
delivered to cells encapsulated in polystyrene micro-
spheres, once inside cells, the nanoparticles can be used
for fluorescent labelling [4]. Palladium(II) compounds
such as [Pd(OAc)2(ADHP)2] (ADHP = 2-amino-4,6-dihy-
droxypyrimidine), can also catalyse Suzuki–Miyaura
cross-coupling and have been used to label modified I-
containing proteins on cell surfaces with fluorescent tags
bearing boronic acid in Escherichia coli [5–7]. Similarly, the
complex [Pd(OAc)2(N,N-dimethylADHP)2] has been
used for fluorescent-labelling of homopropargylglycine-
modified ubiquinone and peptides via a copper-free
Sonogashira reaction [8]. Copper-free Shonogashira in
modified E. coli and Shigella cells has also been per-
formed using Pd(NO3)2 to fluorescently label allyl-con-
taining proteins [9]. Copper(I) has been used to perform
azyl–alkyne cycloadditions in combination with ligands
such as TBTA, THPTA, BTTAA or BTTES (Figure 1).
Using such a method, different cell membrane proteinswww.sciencedirect.com
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Table 1
Examples of metal catalysis studied in cellulo or in vivo
Metal complex Reaction Function/use Cell system
C–C bond formation
Cu(I)-TBTA (or similar) Azyl–alkine
cycloadditions
Labelling of modified proteins containing
alkyne or azyl groups
E. coli, HeLa, CHO,
Jurkat cells, Zebra fish
[Pd(OAc)2(ADHP)2] Suzuki–Miyaura cross
coupling
Fluorescence labelling of cell-surface proteins E. coli
[Pd(OAc)2(DMDHP)2] Cu-free Sonogashira Labelling of alkyl-containing proteins E. coli
Pd(NO3)2 Cu-free Sonogashira Labelling of alkyl-containing proteins Shigella cells
Pd0 nanoparticles Suzuki–Miyaura cross
coupling
Fluorescence labelling HeLa cells
Deprotection and functional group modifications
Pd0 nanoparticles
(PET microspheres)
Carbamate cleavage Activation of pro-fluorophores protected by
carbamates
HeLa cells
Pd0 nanoparticles
(PET macrospheres)
Carbamate cleavage
Dealkylation of amines
Activation of pro-fluorophores or pro-drugs Zebra fish
[Pd(dba)2], [(Allyl)PdCl]2 Carbamate cleavage Activation of pro-fluorophores protected by
carbamates; selective activation of proteins
containing lysine protected aminoacids
HeLa, HEK293T, CHO,
CaCo-2, A549, NIH3T3 cells
[Fe(TPP)Cl] Reduction of aromatic
azides
Activation of azides/fluorescence imaging HeLa cells, zebra fish,
Caenorhabditis elegans
[Cp*Ru(h6-pyrene)]PF6 Carbamates cleavage Activation of pro-fluorophores protected by
allyl-carbamates
HeLa cells
[Cp*Ru(COD)Cl] Carbamates cleavage Activation of pro-fluorophores protected by
allyl-carbamates
HeLa cells
[CpRu(QA)(h3-allyl)]PF6 Carbamate cleavage Activation of pro-fluorophores or pro-drugs
protected by allyl-carbamates
HeLa cells
Degradation of biomolecules
Cu(II)-ATCUN-R Cleavage of RNA Hepatitis C and HIV Huh7 cells (Hepatitis C)
Jurkat cells (HIV)
Ni(II)-ATCUN-R Cleavage of RNA Hepatitis C and HIV Huh7 cells (Hepatitis C)
Jurkat cells (HIV)have been labelled with fluorescent tags in E. coli, HeLa,
CHO and Jurkat cells [10,11]. More interestingly, the
reaction was also executed successfully in mammalian
cells and embryonic zebra fish [12]. This topic has been
extensively reviewed recently [13–15].
Deprotection and functional group modification
This area of research is remarkably young with only
limited examples, but shows much promise. Examples
are the Pd0 nanoparticles mentioned above for the
Suzuki–Miyaura reaction [4]. Such particles encapsulated
in polystyrene microspheres catalyse the cleavage of allyl-
carbamate protected groups [4]. The catalytic reaction is
effective in HeLa cells where allyl-carbamate-protected-
rhodamine 110 was administered before the administra-
tion of the nanoparticles, giving intense fluorescence after
the liberation of rhodamine 110 [4].
A similar approach has also been used for the activation of
drugs such as modified 5-fluorouracyl, protected at the N1
with allyl, propargyl or benzyl groups. The modified drug
was administered and activated in zebra fish by Pd0
nanoparticles attached to macrospheres of polystyrene
(150 mm diameter, larger than human cells). The Pd0
nanoparticles are capable of catalysing the extracellular
dealkylation of the N-alkyl fluoracyl [16]. The same Pd0www.sciencedirect.com nanoparticles also activated pro-drugs protected with
carbamates such as gemcitabine [17].
Meggers et al. have reported a series of compounds which
are capable of cleaving carbamates in protected amines,
using RuII compounds instead of Pd0, for example,
[(Cp*)Ru(COD)Cl] (COD = cyclooctadiene) (Figure 1)
[18,19] and [(Cp*)Ru(h6-pyrene)]PF6. The latter is inac-
tive until irradiated with light (l = 330 nm) and further
releases the pyrene moiety. Both complexes activate a
derivative of rhodamine 110 protected with allyl-carba-
mates in HeLa cells (Figure 1). However, the presence of
thiols is required [19,20]. More recently, the catalytic
cleavage of allyl-carbamates in cells has been greatly
improved by the use of the RuIV complexes such as
[CpRu(QA-R)(h3-allyl)]PF6 (QA = 2-quinolinecarboxy-
late; R = p-donating groups). These also activate pro-
tected fluorophores and protected anticancer drugs
such as N-(allyloxycarbonyl) doxorubicin, inside HeLa
cells [21].
Chen et al. have recently reported the use of four Pd
compounds as catalysts for the deprotection of carba-
mates. These compounds were tested for the deprotec-
tion of allyl-carbamate-protected and propargyloxy-
carbamate-protected rhodamine 110 and also protectedCurrent Opinion in Chemical Biology 2015, 25:172–183
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Chemical structures of metal catalysts. (a) Formation of C–C bonds in cells, (b) deprotection and functional group modification, and
(c) degradation of biomolecules.lysine residues. Those experiments were carried out in six
different mammalian cell lines. The more effective com-
pounds were [(allyl)PdCl]2 and [Pd(dba)2] (dba = diben-
zylideneacetone) (Figure 1). This method was then
readily applied to synthetic proteins containing protected
lysine, showing that protein controlled activation can be
achieved in cells and in vivo [22].
With a similar aim, Meggers et al. reported the use of the
iron complex [Fe(TPP)Cl] (TPP = 5,10,15,20-tetraphe-
nylporphyrin) as a catalyst for the reduction of azides to
imines in cells, in the presence of thiols or other reducing
agents (Figure 2) [19,23]. This compound has been
studied for the activation of a rhodamine 110 derivativeCurrent Opinion in Chemical Biology 2015, 25:172–183 that contains azides instead of amines in HeLa cells,
Caenorhabditis elegans and zebra fish [23]. The topic has
been recently reviewed by Meggers et al. [24].
Degradation of biomolecules
The development of catalytic drugs for the hydrolytic
and oxidative cleavage of peptide/proteins has been
investigated for several years. A few of these reported
metal complexes have shown potential as therapeutic
agents. For example CuII-1,10-phenanthroline-
arenesulphonamide (Cu-OP-CBSA) complexes can target
carbonic anhydrase and catalyse the hydrolytic cleavage
the protein [25]. Similarly, FeIII- or CuII-containing
EDTA–biotin conjugates catalyse the oxidative cleavagewww.sciencedirect.com
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GSH oxidation. (a) Chemical structures of the complexes tested for the catalytic oxidation of GSH in cells. (b) Effects induced by artificial GSH
oxidation in cells. Arene = hmb, p-cym or bip. R0 = NMe2, OH or H; R00 = CH2Ph, CH2CH2Ph or CH2C6H4-p-tBu.of streptavidine [26]. The CoII complex, [Co(cycle-
n)(OH2)2]
3+ (Figure 1) can cleave peptide deformylase
under physiologically-relevant conditions, and that could
be attractive as an antibiotic agent [27]. Recently, Suh
et al. have reported catalytic applications of [Co(cy-
clen)(H2O)2]
3+ for performing hydrolytic cleavage of amy-
loids at 310 K and pH 7.4 [28–31]. Amyloids are insoluble
aggregations of peptides or proteins, and are present in
conditions such as Alzheimer’s, Parkinson’s and Type IIwww.sciencedirect.com diabetes. NiII and CuII compounds containing an ATCUN
motif (an amino terminal peptide with His in position 3)
have also been shown to cleave proteins catalytically. For
example, the metal complex of ATCUN-lisinopril catalyt-
ically cleaves angiotensin-converting enzyme [32].
Many of the aforementioned compounds can also be
conjugated to RNA or DNA targeting vectors, in
order to cleave nucleic acid chains specifically. RecentCurrent Opinion in Chemical Biology 2015, 25:172–183
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et al. which are designed to target hepatitis C and degrade
its RNA [33,34]. Cowan et al. have also reported the use of
CuII and NiII ATCUN compounds to recognize and
cleave HIV1 RNA [35,36]. Both ATCUN type com-
pounds were active in cells. Other examples of NiII, FeII,
FeIII, CoIII, CuII as well as other metals, containing
ligands capable of recognizing specific peptides or
RNA have been reported and reviewed [37–40].
Modulation of the redox environment
In general, a very tight balance is maintained between the
reducing and oxidizing agents present in cells. Oxidative
stress caused by the imbalance between reactive oxygen
and/or nitrogen species (ROS, RNS) and biological anti-
oxidants can lead to alterations in biomolecules such as
DNA, lipids and proteins. The redox status of cells is also
critical in the regulation of gene expression and some
signalling pathways. Despite the fact that ROS and RNS
are necessary for the normal physiological functioning of
the cell, over production of redox active species may
result in cell dysfunction or death. Alzheimer’s, Parkin-
son’s, arteriosclerosis or cancer are some of the diseases
that have been linked to oxidative stress [41]. Hence,
there is increasing interest in modulating the redox bal-
ance. We discuss briefly four different classes of redox
modulators.
Photosynthetizers used in photodynamic therapy
PDT relies on the administration of a non-cytotoxic
compound (photosensitizer) which can be excited by light
irradiation, at a specific wavelength. The excited com-
pound promotes the formation of highly reactive singlet
oxygen (1O2) from ground-state triplet oxygen. Singlet
oxygen, like other reactive oxygen species (ROS), causes
damage and oxidative stress when in high concentrations
[42]. The photosensitizer should ideally be activated at
long wavelength in order to achieve deeper penetration in
the body. Most photosensitizers are highly conjugated
macrocycles such as porphyrins, chlorins or naphthalo-
cyanines. There are a few examples of metal complexes
that have been studied for that purpose. Some metallo-
macrocycles have reached clinical trials, including alu-
minium sulphonated-phthalocyanine (approved for clini-
cal use in Russia), motexafin lutetium and palladium
bacteropheophorbide. This topic has been extensively
reviewed [42] and we will not discuss it in the present
review.
Superoxide dismutase mimics
Metal-complexes can catalyse the dismutation of super-
oxide radicals (O2
), toxic reactive oxygen species gen-
erated by different metabolic pathways but mainly in the
mitochondrial electron transport chain. Suitable SOD
mimics require a redox potential between 180 mV
(reduction potential O2
 referenced to hydrogen elec-
trode) and +890 mV (oxidation potential of O2
), thusCurrent Opinion in Chemical Biology 2015, 25:172–183 mimicking the thermodynamic and kinetic properties of
the original SOD enzymes [43–46]. In mitochondria, SOD
is a manganese (MnII/MnIII) enzyme, and in the cytoplasm
a CuI/IIZnII enzyme. Manganese SOD mimics containing
polydentate macrocycles such as porphyrins, corroles,
salens, biliverdins or polyamines in particular have shown
promise and some have undergone clinical trials (e.g.,
M40403 for treatment of metastatic melanoma and renal
cell carcinoma, currently in clinical trial NCT00033956).
There are many reviews related to SOD mimics [43–46]
and we will not discuss them further here.
Oxidation of thiols
Thiol groups play critical roles in the folding and stability of
proteins and enzymes. Reduced cysteines and oxidized
cystine disulphide cross-links are redox pairs, although
there are several other important oxidation states of sul-
phur (including sulfenate, sulfinate, and sulfonate). Thus,
thiols play an important role in controlling and maintaining
the redox homeostasis of cells, and can provide protection
against elevated levels of reactive oxygen species. The
redox state of sulphur is involved in cellular signalling.
Thiol groups are therefore targets in the development of
catalytic drugs. For example, anti-cancer half-sandwich
RuII complexes containing azopyridine (Azpy) chelating
ligands (Figure 2), can oxidize glutathione (GSH) to
GSSG catalytically [47]. Glutathione is a cysteine-con-
taining tripeptide, g-L-Glu-L-Cys-Gly, which is of critical
importance for the maintenance of the redox homeostasis
of the cell. GSH can act as an antioxidant and prevent
damage by reactive oxygen and nitrogen species (ROS,
RNS) [48,49]. As a consequence of the treatment of
cancer cells with azopyridine-RuII half sandwich com-
pounds, the levels of GSH in cells are lowered and the
redox balance of the cell disrupted. A549 cancer cells
show an increase of ROS levels upon 24-hour exposure to
the complex. Interestingly, the OsII analogues show very
different reactivity and do not oxidize GSH [50].
In addition to the effects on the redox balance, the
depletion of GSH may also interfere with other cellular
processes since GSH is not only an antioxidant but is also
involved in detoxification. Many internal and external
toxins react with GSH to form GS-X adducts, that are
excreted from the cell or the body [48,49]. GSH is also
involved in some metabolic processes, including storage
and transport of nitric oxide, metabolism of estrogens,
leukotrienes, and prostaglandins, reduction of ribonucleo-
tides; maturation of iron–sulphur clusters of diverse pro-
teins, and operation of some transcription factors [49].
To explore this approach further, a series of RuII complexes
containing redox-active o-phenylenediamine  (o-pda) che-
lating ligands have been designed (Figure 2). These com-
plexes undergo ligand oxidation in the presence of oxygen,
generating [(h6-arene)Ru(o-benzoquinonediimine)Cl]+www.sciencedirect.com
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GSH to regenerate the complex. These complexes can
also catalytically oxidize up to 15 mol equivalents of
GSH in 72 hours, under biologically relevant conditions
[51]. The compound showed no antiproliferative activity
in cells, perhaps because the catalysis is not efficient enough
[51].
Surprisingly, the ruthenium complex [(bip)Ru(en)Cl]+
(en = ethylenediamine) also reacts with GSH at pH
7 in the presence of oxygen to give the sulphenato-GS
adduct (Figure 2) [52,53]. Bound sulfonate appears to be
more readily displaced (e.g., by G on DNA) than the
thiolate, but this reaction has yet to be studied as a
catalytic process.
Thiolate-bridged ruthenium(II) arene dimers of the type
[(h6-arene)2Ru2(SR)3]
+ and [(h6-arene)2Ru2(SR)2Cl2] are
known to oxidize thiols (Figure 4). Recently, Therrien
et al. have shown that catalysis can occur under biological
conditions. The RuII dimers exhibit high antiproliferative
activity against a range of cancer cell lines, including
cisplatin-resistant cells, however the anticancer activity
does not correlate with the catalytic activity of the dimers
[54–56]. The catalytic activity may not be the main anti-
cancer mechanism but could contribute. The RhIII and
IrIII analogues of the RuII dimer show similar antiproli-
ferative activity [54], although the catalytic activity to-
wards oxidation of GSH is markably lower than with RuII
compounds.
The RuII cages [( p-cym)6Ru6(2,4,6-tri(pyridine-4-yl)1,3,5-
triazine)2 (1,4-benzoquinonato)3]
6+ and [( p-cym)6Ru6(2,4, 6-
tri(pyridine-4-yl)1,3,5-triazine)2(5,8-dihydroxy-1,4-naphtho-
quinonato)3]
6+ synthesized as carriers for transport of cyto-
toxic molecules into cancer cells, also oxidize GSH.
However, the active species is the product of the reaction
between the {(p-cym)Ru}2+ and GSH or some amino acids.
The metallo-cages undergo ligand substitution and form
RuII species capable of oxidizing GSH under biological
conditions. Interestingly, in competition reactions involving
various amino acids and cysteine or GSH (Figure 2), the
catalytic properties are retained [57,58].
Despite the success of some complexes in oxidizing
thiols, they are non-specific and many other sulphur-
containing molecules and reducing species often react
with the catalysts. However, some compounds appear to
show a preference for oxidation of thiols in cells which is
encouraging for future tuning and improvement of their
properties.
Complexes for transfer hydrogenation reactions
Transfer hydrogenation reactions are usually defined as
the reduction process by which a catalyst can promote the
transfer of a hydride ion from a donor to a molecule
containing a multiple bond. Traditionally, this reactionwww.sciencedirect.com has been used for the reduction of ketones, imines and
C C double bonds in non-aqueous (usually alcoholic)
media, using 2-propanol/KOH or formic acid/triethyla-
mine as hydride donors[59]. However, the reductions can
be carried out in aqueous media using sodium formate as a
hydride source [60]. Such mild conditions allow transfer
hydrogenation reactions to be carried out with biomole-
cules, such as nicotinamide adenine dinucleotide or py-
ruvate.
In the field of hydrogenation and transfer hydrogenation
reactions, regeneration of NADH and NAD+ has been
intensively studied, mainly for enzymatic reduction in
organic synthesis [61]. The first series of complexes
reported which were capable of reducing NAD+ to
NADH via transfer hydrogenation was that of Steckhan
et al. Organometallic RhIII bipyridine complexes were
shown to reduce NAD+ efficiently with high turnover
frequencies. The mechanism and applications for the
reduction of ketones (complex-NAD-enzymatic system)
using [(Cp*)Rh(bipy)Cl]+ (Figure 3) have been well
studied by Fish et al. [62–67]. Su¨ss-Fink et al. reported
the catalytic reduction of NAD+ by a series of phenan-
throline-containing RuII, RhIII and IrIII catalysts [68].
The RuII half sandwich compounds were shown to be
much less active than their RhIII and IrIII analogues. The
complex [(Cp*)Rh(phen)Cl]+ (Figure 3) achieved con-
versions and turnover frequencies of up to twice those
obtained previously with [(Cp*)Rh(bipy)Cl]+ in aqueous
media, at 333 K and pH 7 [68]. Subsequently the catalytic
regeneration of 1,4-NADH by some RuII complexes
containing ethylenediamine or acetylacetonate ligands
was studied (Figure 3), but the turnover frequencies were
low [69]. Salmain et al. prepared a series of RhIII and RuII
complexes using dipyridyl amine ligands functionalized
by maleimide. The complexes were not as active as the
bipyridine-containing complex [(Cp*)Rh(bipy)Cl]+, but
comparable turnover frequencies and conversions were
achieved with a RhIII complex containing a 2,2-dipyridy-
lamine-maleimide ligand [70].
Poisoning of the metal catalysts when the system is
coupled to alcohol dehydrogenase or other enzymes,
mainly by reaction with thiol groups, has been reported
and is often a feature of such systems [71]. A common
approach to avoid catalyst inactivation has been to attach
the catalyst to a solid support. For example, Hollmann
et al. used a tethered RhIII-Noyori type complex immo-
bilized on a poly(ethylene) polymer (Figure 3c) [72]. The
catalytic activity of the heterogeneous catalyst was lower
than that of other soluble RhIII complexes. This area has
been reviewed [71].
Recently, Ward et al. incorporated biotin–streptavidin
into Noyori-type IrIII complexes, thus creating artificial
metalloenzymes with higher activities than the well-
established [Cp*Rh(bipy)Cl]. The conjugate wasCurrent Opinion in Chemical Biology 2015, 25:172–183
178 Biocatalysis and biotransformation
Figure 3
(a) 
(b) 
(c) 
(d) 
H
O
O
(n+1)+
NAD+
NADP+ NAD+
NADPH
NADH
HCOO–
M M N
N
O
O
O
O Support
N
H
Ir
CI
O
S
N
Arena
Arena
Ru
Ru
CI
CI
O
O
H
N
CI
S
Rh
N
NH
N
N
H2O CO2
H2O
M
N
1,4-NADH
N
O
O
H
N
N
M
Rh
CI CI
Rh
N
N
N
N
n+ n+
n+
+
+ +
N
H
H2N
H
O
S NH
N
H2N
H2N
NH2
N O
O
S
R
NA
D
+ /NA
DH
 rat
io
[(Cp*)Rh(bipy)Cl]+ [(Cp*)Rh(phen)Cl]+ 
RhIII-TsDPEN-poly(ethylene)
[(Cp*)Ir(biot-p-L)Cl] 
[(arene)Ru(TsEn)Cl][(arene)Ru(en)Cl]+ 
Mitochondrial function, energy (TCA),
DNA repair and transcription, antioxidant,
calcium homeostasis, signalling 
Antioxidant,
synthesis GSH
Increase of ROS
(at very high conc.)
Current Opinion in Chemical Biology
Regeneration of NADH. (a) Scheme for the catalytic process inside cells. (b) Summary of some of the relevant functions of NAD+ in cells. (c)
Chemical structures of some of the complexes studied for regeneration of NADH. (d) Chemical structures of the ruthenium catalysts that have
been studied in cells. Arene = bn, hmb, p-cym or bip. R = p-tosyl, methyl or p-trifluoromethylbenzene.designed to circumvent catalyst poisoning. Although the
IrIII was still poisoned by the addition of nucleophiles
such as glutathione, co-administration of the compound
with oxidizing agents, capable of oxidizing GSH, resulted
in a significant increase in the catalytic activity of the
complex [73]. They also demonstrated that [Cp*Ir(biot-p-
L)Cl] anchored within streptavidin can be used as an
asymmetric transfer hydrogenase with a variety of redox
enzymes relying on NADH, FADH2 and haem cofactors
[74].Current Opinion in Chemical Biology 2015, 25:172–183 In our more recent work, we have focussed on the
modulation of the NAD+/NADH ratio in cells using
organometallic complexes such as [(hmb)Ru(en)Cl]+
or [( p-cym)Ru(TsEn)Cl] (TsEn = N-(2-aminoethyl)-4-
toluenesulphonamide) [69]. The concentration of NAD+
as well as the NAD+/NADH ratio play crucial roles in
many cellular metabolic processes such as regulation of
energy metabolism, DNA repair and transcription, im-
munological functions and cell death [61,75,76]. Fur-
thermore, changes in metabolism result in fluctuationswww.sciencedirect.com
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the ratio can produce metabolic changes [61,75,76].
In some cases alterations in the cellular redox status
play an important role in cell death, making the
coenzymes potential drug targets for chronic or auto-
immune diseases such as Parkinson’s, hepatitis C,
diabetic vascular dysfunction, hyperglycaemia and
cancer [61,75,76]. Cancer cells, due to their increased
rate of metabolism, generate high levels of oxidizingFigure 4
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www.sciencedirect.com species and, therefore, are under constant oxidative
stress [77]. This makes cancer cells more dependent
on redox regulatory systems, and more sensitive to
variations in the NAD+/NADH ratio. In addition,
NAD+ is also required as a substrate for the synthesis
of ADP-ribose, ADP-ribose polymers and cyclic
ADP-ribose which are crucial for genome stability,
DNA repair and maintenance of calcium homeostasis
[76].(b) 
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180 Biocatalysis and biotransformationHuman lung A549 cancer cells for example, can tolerate
millimolar levels of formate, but in the presence of
[(hmb)Ru(en)Cl]+ no significant effect on cell growth
was observed [69]. We hypothesized that, in order to
catalyse the reduction of NAD+ in cells, more active
catalysts are required. Recently, water-soluble RuII
Noyori-type complexes such as [( p-cym)Ru(TsEn)Cl]
(Figure 3) were shown to reduce NAD+ to NADH, with
turnover frequencies of up to 10 times higher than their
ethylenediamine analogues [78]. These Noyori-type
complexes are capable of reducing the levels of NAD+
in A2780 ovarian cancer cells when co-administered with
sodium formate, potentiating the antiproliferative activity
of the complexes, such that their activity is comparable
with the clinical drug cisplatin [79].
Regeneration of NAD+ by transfer hydrogenation and
oxidation of NADH has also been studied. The water-
soluble iron(III) porphyrin [Fe(TSPP)Cl] (TSPP =
meso-tetrakis(4-sulphonatophenyl)porphyrin) catalyses
the oxidation of NADH using O2 as an electron acceptor,
at pH 7 and ambient temperature (Figure 4) [80].
Fukuzumi et al. reported the regeneration of NADH
using [(Cp*)Ir(4-(1H-pyrazol-1-yl-kN2)benzoic acid
kC3)H2O)]2SO4 and H2 in neutral or slightly basic
media. Interestingly, the IrIII compound regenerated
NAD+ under acidic conditions (pH  3; Figure 4) [81].
The complexes [(h6-arene)Ru(bpm)Cl]+ and [Cpx)Ir
(phen)H2O]
2+ (bpm = bipyrimidine) can utilize NADH
as a hydride source for transfer hydrogenation reactions
involving important biomolecules such as quinones and
pyruvate [82].
Incubation of A2780 ovarian cancer cells with [Cpx)Ir(-
phen)H2O]
2+ increases the NAD+/NADH ratio after
24 hours exposure [82]. Similarly, the IrIII complex
[(CpXbiph)Ir(phpy)py]+ (phpy = phenylpyridine), can uti-
lize NADH as a biological hydride donor, to generate an
iridium-hydride complex capable of increasing the levels
of reactive oxygen species in cancer cells [83]. Thus,
offering an alternative mode of action compared to cis-
platin [83].
We have also shown that OsII compounds such as [(are-
ne)Os(Impy-NMe2)X]PF6 (X = Cl
, I; arene = p-cym,
bip; Impy = iminopyridine) can oxidize NADH via trans-
fer hydrogenation reactions, possibly generating hydro-
gen peroxide (Figure 4) [84]. The NAD+/NADH ratio in
A2780 cancer cells increases upon treatment with the
osmium compound as do the ROS levels. Oxidation of
NADH may be involved in the mechanism of action of
these complexes [84].
Currently, transfer hydrogenation reactions in cells
appear to be promising as part of the mechanism of action
of metal anticancer agents. The next challenge will be to
introduce more selectivity into substrate recognition.Current Opinion in Chemical Biology 2015, 25:172–183 Concluding remarks
Catalysis by metal complexes is well known in chemical
systems and widely used. Whether the chemical catalysis
is homogeneous or heterogeneous, it is usually carried out
in well-defined media so as to avoid catalyst poisoning.
Control over the type of transformation and, in particular
the stereochemical course of the reaction, is often
achieved by the choice of metal, types and number of
ligands and coordination geometry of the complex.
Our brief review illustrates that catalysis with low-molec-
ular-weight metal complexes can successfully be
achieved in biological systems. Some remarkable recent
examples of metal-based catalytic drugs include the use
of CuI/TBTA (or similar) compounds to label proteins
in vivo, Pd0 nanoparticles that activate anti-cancer drugs,
the controlled activation of proteins by using Pd0 com-
plexes, CuII-ATCUN compounds which target and de-
grade hepatitis C and HIV RNA, and the achievement of
transfer hydrogenation reactions by IrIII and RuII half
sandwich complexes. Altogether, this suggests that fur-
ther progress can be achieved in this field, with the
prospect of leading to novel drugs for clinical trials.
Of special interest to our research is the development of
redox-modulating drugs. Such approach has already been
shown to be successful in areas such as the clinical use of
aluminium sulphonated phthalocyanine for PDT, and
Mangafodipir or Calmangafodipir as SOD mimics. It is
apparent that other approaches such as thiol oxidation and
transfer hydrogenation reactions are also promising. How-
ever, these approaches are still all in their infancy, and
will be aided by future advances in design which increase
substrate selectivity and efficiency.
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